Questo è quello che abbiamo trovato per te
This nonrandomized clinical trial examines the activity and safety of camrelizumab plus apatinib and temozolomide as first-line treatment in patients with advanced acral melanoma.
This cohort study examines mortality and factors associated with mortality after a diagnosis of melanoma in situ.
In this issue of JAMA Dermatology, Patel and colleagues examine mortality after a diagnosis of melanoma in situ. Melanoma in situ is the earliest stage of melanoma (stage 0) and is localized to the outermost layer of skin (epidermis). It is regarded as a potential precursor lesion to invasive melanoma (stages I to IV), in which melanoma invades the deeper layers of the skin and, in doing so, acquires the potential ability to spread to distant sites, which may ultimately lead to death from melanoma. Nevertheless, melanoma in situ is not an obligate precursor of invasive melanoma, and it is increasingly acknowledged that some lesions diagnosed as melanoma are clinically indolent and will never progress. The latter scenario is often referred to as overdiagnosis of melanoma.
This cohort study compares outcomes associated with wide- vs narrow-margin excisions in patients with T1a melanoma near critical structures.
In Italia un terzo dei morti nell’Ue per i super batteri
This consensus statement provides consensus recommendations on optimal screening practices and prebiopsy diagnostic, postbiopsy diagnostic, and prognostic assessment of cutaneous melanoma.
Melanoma mortality has declined over the past decade, largely due to availability of dramatically more effective treatments of advanced disease, but melanoma remains an important public health problem due to a persistent significant mortality risk as well as morbidity and cost. In this issue, Kashani-Sabet et al report early detection and prognostic assessment recommendations of a large group of experts using a modified Delphi approach. We consider these recommendations from 3 perspectives: the role of risk stratification, the role of gene expression profiling (GEP), and the hierarchy of evidence as it pertains to public health.
This cohort study examines the association between habitual diet and response to treatment with immune checkpoint blockade among patients with advanced melanoma.
Studio Moderna e Merck,sfrutta tecnologia a mRNA usata per Covid
Analizza informazioni su dati genomici concentrandosi su 31 geni
Le strategie in un documento presentato da Farmindustria
Ministro, siamo concentrati su aumento coperture vaccinali
To the Editor We read with tremendous enthusiasm the original investigation by Dr Adamson and colleagues demonstrating the prominence of high diagnostic scrutiny in melanoma incidence and the necessity to take seriously the role it plays in melanoma mortality. What intrigued us is the study’s conclusion that UV radiation exposure has a weak association with melanoma incidence in the US, shattering the long-standing perception of UV radiation as a formidable risk factor. If the conclusion holds true, it will alleviate the unease to some extent and downsize the magnitude of risk factors, among which UV radiation has been the most widely accepted and biggest culprit for melanoma.
This scoping review describes strategies to improve adherence to self-management practices in randomized clinical trials of people at high risk of melanoma.
In Reply We appreciate the tremendous enthusiasm with which Drs He and Huang read our article highlighting the weak association between proxies for UV radiation exposure and melanoma incidence across US counties. Although this revelation may be surprising to some readers and could shatter long-standing perceptions for others, it is not a new finding. The meta-analytic relative risk for the strongest UV-related risk factor—sunburn history—is only 2.0. This relatively weak association is not recognized by the wider public because sun exposure and its association with melanoma are too often (and inappropriately) compared with smoking and lung cancer (relative risk, 10.0-20.0). Although UV radiation exposure may be a modifiable risk factor for melanoma, it is certainly not formidable.
This JAMA Patient Page describes melanoma, its risk factors, diagnosis, treatment, and prognosis.
